Van Vuurden et al. (81) observed an overexpression of PARP1 as well as a radiosensitizing effect by the PARP1 inhibitor olaparib in pediatric medulloblastoma, ependymoma, and high grade glioma cell lines. Here, PARP1 is linked to central nervous system cancer.